Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study

  • Authors: M. F. Morelli, A. Santomaggio, E. Ricevuto, K. Cannita, F. De Galitiis, M. Tudini, G. Bruera, M. Mancini, M. Pelliccione, F. Calista, F. Guglielmi, F. Martella, P. Lanfiuti Baldi, G. Porzio, A. Russo, N. Gebbia, S. Iacobelli, P. Marchetti, C. Ficorella
  • View Affiliations

  • Published online on: Tuesday, June 1, 2010
  • Pages: 1635-1640
  • DOI: 10.3892/or_00000805

Abstract

A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irinotecan 160 mg/m2; oxaliplatin 80 mg/m2; 5-FU 900 mg/m2. The dose-limiting toxicity was diarrhea (35% of patients) but no cases of febrile neutropenia were observed. In 30 patients assessable for response two complete (6.7%) and 18 partial (60%) responses were observed, for an overall response rate of 66.7% (α0.05, CI±17). The triplet association using this weekly alternating schedule is an active and well-tolerated outpatient regimen. Surgical removal of residual disease was considered in 5 patients and a radical resection was performed in 5 patients (147percnt;).
Journal Cover

June 2010
Volume 23 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

2012 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Morelli, M., Santomaggio, A., Ricevuto, E., Cannita, K., De Galitiis, F., Tudini, M., Bruera, G., Mancini, M., Pelliccione, M., Calista, F., Guglielmi, F., Martella, F., Lanfiuti Baldi, P., Porzio, G., Russo, A., Gebbia, N., Iacobelli, S., Marchetti, P., & Ficorella, C. (2010). Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study . Oncology Reports, 23(6), 1635-1640.
MLA
Morelli, Santomaggio, Ricevuto, Cannita, De Galitiis, Tudini, Bruera, Mancini, Pelliccione, Calista, Guglielmi, Martella, Lanfiuti Baldi, Porzio, Russo, Gebbia, Iacobelli, Marchetti, and C. Ficorella. "Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study ." Oncology Reports Oncology Reports 23.6 (2010): 1635-1640.
Chicago
Morelli, Santomaggio, Ricevuto, Cannita, De Galitiis, Tudini, Bruera, Mancini, Pelliccione, Calista, Guglielmi, Martella, Lanfiuti Baldi, Porzio, Russo, Gebbia, Iacobelli, Marchetti, and C. Ficorella. "Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study ." Oncology Reports Oncology Reports 23 no. 6 (2010): 1635-1640.